No Data
Minsheng Securities: The advantages of CGM real-time blood glucose monitoring are significant, with outstanding clinical value.
Driven by factors such as the deepening global aging population, the increasing demand for the diagnosis and treatment of diabetes patients, and the gradual improvement of the healthcare insurance system, the CGM industry will experience continuous growth.
Sinocare Inc. (300298.SZ): Currently, both semi-automated and fully automated production lines for CGM have been completed.
On December 17, Gelonghui reported that Sinocare Inc. (300298.SZ) recently stated during investor relations activities that both its semi-automated and fully automated production lines for CGM have been established. The company will dynamically adjust production according to the development and sales demand of its CGM products to meet the needs of domestic and foreign markets.
Sinocare Inc. (300298.SZ): The continuous glucose monitoring system has obtained the medical instruments registration certificate.
Sinocare Inc. (300298.SZ) announced that the company recently received two "Medical..." certifications issued by the National Medical Products Administration.
Optimism for Sinocare (SZSE:300298) Has Grown This Past Week, Despite Five-year Decline in Earnings
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Sinocare Signs Distribution Deal With Italy's Menarini Diagnostics; Shares Up 3%
Sinocare Inc.'s (SZSE:300298) 29% Share Price Plunge Could Signal Some Risk
